ALPMF News and Press, Astellas Pharma Inc From 01/09/24

2024-01-09 05:49:53 ET Japanese drugmaker Astellas Pharma ( OTCPK:ALPMY ) said on Monday that the U.S. Food and Drug Administration (FDA) has declined to approve the biologics license application of its experimental gastric cancer drug due to issues related to a third-party manufact...

2024-01-05 14:30:17 ET More on the markets SPY And QQQ: Fundamentals Remain Strong, Buying The Dip Verily Volatility: SPY Puts Are Cheap And The Market Is Selling Off The Market Looks Poised To Make New Highs In 2024 ETFs attract $597B in 2023 marking the fou...

2023-12-31 01:55:00 ET Summary Elpiscience Biopharma forms a $1.7 billion collaboration with Astellas Pharma to develop a bispecific macrophage engager. AstraZeneca acquires Gracell Biotech in a deal worth up to $1.2 billion, including a clinical stage CAR-T therapy. Jinan Qil...

2023-12-28 04:45:39 ET More on Astellas Pharma FDA approves Keytruda/Padcev combo therapy for bladder cancer Biden eyes seizing patents of taxpayer-funded drugs in bid to slash prices Seeking Alpha’s Quant Rating on Astellas Pharma ADR For further deta...

2023-12-27 12:29:36 ET More on AbbVie, Johnson & Johnson, etc. Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase Eli Lilly: Consider Cutting Before The Southbound Train Leaves (Rating Downgrade) AbbVie Vs. GSK: Dual Dominance In Pharma ...

2023-12-15 18:20:05 ET More on Merck, Pfizer, etc. Pfizer: Dividend Boost At The Right Time Pfizer 2024 Guidance - Relentless COVID Pain Isn't Over Johnson & Johnson Vs. Pfizer: Better Pharma Stock? Merck gets FDA approval for kidney cancer drug Welireg ...

2023-12-14 07:47:47 ET More on Apellis Pharma Apellis Pharmaceuticals: Focus Shifts Toward Market Share After Apparent Safety Resolution Apellis Pharmaceuticals, Inc. (APLS) Q3 2023 Earnings Call Transcript Apellis Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings C...

2023-12-08 04:54:49 ET More on Pfizer, Astellas Pharma Johnson & Johnson Vs. Pfizer: Better Pharma Stock? Pfizer: This Year's Disaster Should Set The Stage For A Strong 2024 Pfizer: Slimming Down After COVID Franchise And Obesity Pipeline Setbacks Astella...

2023-12-06 11:19:36 ET Summary Apellis addressed Syfovre's safety issues, improving its situation; still, initial concerns about severe side effects remain relevant. Syfovre's market potential is significant as the first GA treatment, but rare vasculitis cases and competition pose...

2023-12-01 09:18:27 ET More on Apellis Pharmaceuticals Apellis Pharmaceuticals, Inc. (APLS) Q3 2023 Earnings Call Transcript Apellis Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation Apellis Pharmaceuticals: Looking For Entry Around Crucial Q3 Earn...